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The sites of glycosylation of Chinese hamster ovary
cell expressed testicular angiotensin-converting en-
zyme (tACE) have been determined by matrix-assisted
laser desorption ionization/time of flight/mass spec-
trometry of peptides generated by proteolytic and cyan-
ogen bromide digestion. Two of the seven potential N-
linked glycosylation sites, Asn90 and Asn109, were found
to be fully glycosylated by analysis of peptides before
and after treatment with a series of glycosidases and
with endoproteinase Asp-N. The mass spectra of the gly-
copeptides exhibit characteristic clusters of peaks
which indicate the N-linked glycans in tACE to be
mostly of the biantennary, fucosylated complex type.
This structural information was used to demonstrate
that three other sites, Asn155, Asn337, and Asn586, are
partially glycosylated, whereas Asn72 appears to be fully
glycosylated. The only potential site that was not modi-
fied is Asn620. Sequence analysis of tryptic peptides ob-
tained from somatic ACE (human kidney) identified six
glycosylated and one unglycosylated Asn. Only one of
these glycosylation sites had a counterpart in tACE.
Comparison of the two proteins reveals a pattern in
which amino-terminal N-linked sites are preferred. The
functional significance of glycosylation was examined
with a tACE mutant lacking the O-glycan-rich first ami-
no-terminal 36 residues and truncated at Ser625. When
expressed in the presence of the a-glucosidase I inhibi-
tor N-butyldeoxynojirimycin and treated with endogly-
cosidase H to remove all but the terminal N-acetylglu-
cosamine residues, it retained full enzymatic activity,
was electrophoretically homogeneous, and is a good
candidate for crystallographic studies.
Both forms of angiotensin-converting enzyme (ACE1; EC
3.4.15.1 peptidyl-dipeptidase A) are class I transmembrane
ectoenzymes (1) that have N- and O-linked oligosaccharides
attached to their polypeptide chains (2, 3). Expression of ACE
in human HeLa cells in the presence of tunicamycin resulted in
complete inhibition of glycosylation, rapidly degraded intracel-
lular ACE, and no enzyme released in the medium (4). An
enzymatically active ACE was produced with partial glycosy-
lation in a mutant Chinese hamster ovary (CHO) cell line
(ldlD), although it was released to a lesser extent (4). Similarly,
it was reported (5) that inhibitors of glucosidases I and II in the
endoplasmic reticulum (ER) and mannosidase I in the cis-Golgi
reduced the amount of oligosaccharide attached to human in-
testinal ACE and delayed protein release significantly. These
data strongly suggest that glycosylation plays an important
role in the membrane targeting and release of ACE, possibly by
affecting the folding of the polypeptide and its recognition by a
variety of enzymes in the folding and transport machineries.
Recently, Sadhukhan and Sen (6) reported that mutations at
individual N-linked glycosylation sites (sequons) in rabbit tes-
tis ACE (tACE) resulted in varied efficiencies in enzyme re-
lease, which suggests that N-linked glycans at each site may
make different contributions to ACE transport and release.
Comparison of the cDNA sequences of ACE in human, rabbit,
and mouse further supports such a role for glycosylation in
ACE. Five of the seven potential N-linked glycosylation se-
quons in human tACE have counterparts in rabbit, and a sixth
sequon is also present in mouse. It is not known whether the
two additional N-linked glycosylation sequons in human tACE
are utilized, although studies have shown heterogeneity across
different species, both in the sites of oligosaccharide attach-
ment and the types of carbohydrate components (3). tACE from
all three species contains a serine/threonine-rich NH2-terminal
motif that is heavily glycosylated, although no apparent func-
tion for the O-glycosylation has been demonstrated (4, 7).
Information on ACE active site residues and structures is
based largely on homology between ACE and other zinc met-
alloenzymes, and attempts to crystallize ACE have not been
successful. It is thought that partial or complete removal of the
carbohydrate might facilitate the crystallization and structural
studies of ACE. Expression of rabbit tACE in Escherichia coli
resulted in a carbohydrate-free form of the protein, but it was
devoid of any enzyme activity (6). Partially glycosylated ACE
proteins generated by transient expression in human HeLa
cells and in yeast were found to be enzymatically active but left
open the question of whether glycosylation affects in any way
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the specific activities of ACE in vitro.
In this study, we have identified the N-linked glycosylation
sites in human tACE expressed in CHO cells by a combination
of enzymatic digestion and chemical cleavage of the protein
followed by mass spectrometry. Four of the five conserved
sequons are glycosylated, and a fifth is likely glycosylated as
well. A sequon that is present in human and mouse but not in
rabbit ACE is partially glycosylated. In addition, we provide
evidence that a chemically homogeneous form of tACE can be
prepared by inhibition of complex N-linked glycosylation and
enzymatic removal of the high mannose oligosaccharides. Ki-
netic analysis indicates that the enzyme is fully active in vitro,
suggesting that it is a good candidate for crystallographic stud-
ies. Our results further support the hypothesis that glycosyla-
tion plays a critical role in the folding of ACE and that the
effects on transport and enzyme release may be site-dependent.
EXPERIMENTAL PROCEDURES
Materials—Endoproteinase Lys-C and Asp-N, peptide N-glycosidase
F, endoglycosidase H, neuraminidase, and O-glycosidase were pur-
chased from Boehringer Mannheim. Cyanogen bromide (CNBr), triflu-
oroacetic acid, and calibration standards (angiotensin, insulin, myoglo-
bin, oxidized insulin B-chain, and tosylphenylalanyl chloromethyl
ketone-treated trypsin) were from Sigma. Glycosylation inhibitor N-
butyldeoxynojirimycin (NB-DNJ) was kindly provided by Searle Co.
Construction of Expression Vector—pEE-ACED36NJ encodes human
tACE that lacks the heavily O-glycosylated, 36-residue NH2-terminal
sequence (7) and is truncated after Ser625, thereby lacking most of the
juxtamembrane stalk as well as the transmembrane and cytoplasmic
domains (8), and was constructed as follows. The 59 half of the ACE
cDNA in the plasmid pLEN-ACE-JMD24 (8) was excised by digestion
with BamHI and NheI (9) and replaced with the similarly digested
fragment from plasmid pLEN-ACED36N (7). pLEN-ACE-JMD24 has an
engineered EcoRI site at nucleotide 1984 in the ACE cDNA (8). The
sequence between nucleotide 1854 (the start of the unique BclI site) and
nucleotide 1990 (the end of the codon for Ser625) in the native ACE
cDNA was amplified by the polymerase chain reaction, using a 39
primer that contained two stop codons (TAA and TAG) after the Ser625
codon, followed by an EcoRI site. The recombinant sequence was in-
serted into the pLEN-ACED36N/JMD24 hybrid cut with BclI and
EcoRI, to generate pLEN-ACED36NJ. The ACED36NJ coding sequence
was excised by digestion of unique XbaI (generated after first subclon-
ing in pBluescript) and EcoRI sites and inserted into the polylinker of
the expression vector pEE14 (10), to generate pEE-ACED36NJ.
Cell Culture, Transfections, and Enzyme Purification—CHO-K1 cells
stably transfected with pLEN-ACEVII and expressing recombinant,
wild-type human tACE were grown and maintained as described (9, 11).
In addition, native CHO-K1 cells were cotransfected with pEE-
ACED36NJ (10 mg) and pSV2NEO (1 mg) by the calcium phosphate
precipitate method, and clones stably resistant to G418 (Geneticin, Life
Technologies, Inc.) were selected and assayed for ACE activity, by
procedures detailed previously (9, 11). Clones stably expressing pEE-
ACED36NJ were further selected for resistance to methionine sulfoxi-
mine and then amplified, as described (10, 12). Methionine sulfoximine-
amplified cells were grown first in GMEM-10 (Life Technologies, Inc.)
containing 10% dialyzed fetal bovine serum (Life Technologies, Inc.)
and 1.5 mM NB-DNJ for 3 days and then refed with GMEM-10, 5%
dialyzed fetal bovine serum, 2 mM NB-DNJ. This medium was changed
twice over a period of 9 days before harvesting. Soluble, recombinant
tACE (wild-type and ACED36NJ), purified from conditioned media by
lisinopril affinity chromatography, was quantitated by amino acid anal-
ysis and assayed for activity, as described (9).
Deglycosylation of ACE—tACED36NJ (12.5 nmol) purified from cul-
tures treated with NB-DNJ was digested with endoglycosidase H (30
milliunits) in 100 mM sodium phosphate, 0.1 mM ZnCl2, 1% bovine
serum albumin, pH 6.0, for 16 h at 37 °C. The endoglycosidase H-
treated ACE was passed through a lectin affinity column consisting of
equal parts of concanavalin A, wheat germ, and lentil lectin, after
equilibration with 20 mM Tris-HCl, 0.5 M NaCl at pH 7.4. The deglyco-
sylated ACE was collected in the break-through. Free oligosaccharides
and any other impurities were removed from the break-through fraction
by a final lisinopril-Sepharose affinity chromatography step. The ho-
mogeneity of the tACED36NJ after deglycosylation was confirmed by
SDS-polyacrylamide gel electrophoresis on a 4–20% acrylamide gel and
MALDI/TOF/MS.
Protein Digestions—Generally 200 ml of endoproteinase Lys-C (0.1
mg/ml in H2O) was added to 0.5 mg of tACE in 100 mM ammonium
bicarbonate, pH 8.5, and the digestion was allowed to proceed for 16 h
at 37 °C. For CNBr digestion, purified tACE (4 nmol) was lyophilized
and dissolved in 70% trifluoroacetic acid (1 ml). CNBr (40 mg) was
added and the reaction mixture incubated at room temperature for 4 h.
The digestion was stopped by the addition of ice-cold water (1 ml) and
kept on ice for 1 h before lyophilization. The dried sample was then
dissolved in 0.1 M ammonium bicarbonate and subjected to reversed
phase HPLC on a C8 column as described below.
Purified human kidney ACE was digested with trypsin, fractionated
by HPLC, and the peptides were sequenced by automated Edman
degradation as described previously (13).
ACE Peptide Deglycosylation—Lyophilized fractions containing gly-
cosylated peptides (2–3 nmol) were dissolved in 200 ml of 20 mM sodium
phosphate, pH 7.2. One aliquot was designated as a control, and 150 ml
was digested with 50 ml of a glycosidase mixture containing neuramin-
idase (5 milliunits), O-glycanase (2.5 milliunits), and peptide N-glyco-
sidase F (0.4 milliunit) at 25 °C for 24 h.
Peptide Separation—Mixtures of peptides (;200 mg in 50–100 ml)
were resolved by reversed phase HPLC using either a C18 Delta-Pak
column, 5 mm, 3.9 3 150 mm (Waters), or a C8 Microsorb-MV column,
5 mm, 4.6 3 250 mm (Rainin), and eluted with a 10–60% gradient of
0.08% (v/v) trifluoroacetic acid in acetonitrile at a flow rate of 1 ml/min.
The UV absorbance was monitored at 214 nm.
Mass Spectrometry—All mass spectra were obtained on a MALDI/
TOF/MS instrument (Voyager-Elite Biospectrometry Workstation, Per-
Septive Biosystems, Inc.). A nitrogen laser (337 nm) was used for
desorption ionization. Measurements were carried out either in the
linear or reflectron mode with mass accuracies of 0.1 and 0.01%, re-
spectively. Spectra were collected over 100 laser shots.
Typical matrices used in these experiments were 3,5-dimethoxy-4-
hydroxycinnamic acid (sinapinic acid) and a-cyano-4-hydroxycinnamic
acid (Aldrich). About 1 ml of sample solution was mixed with 2 ml of the
matrix solution (10 mg/ml in 50% v/v CH3CN and H2O). A 0.5-ml volume
(containing 1–10 pmol of peptide or peptide mixture) of the above
solution was loaded on the sample plate and allowed to dry. All m/z
values reported are isotopically averaged masses.
RESULTS
Determination of N-Linked Glycosylation Sites—Purified hu-
man tACE (wild-type minus COOH-terminal residues 628–
701) was digested with endoproteinase Lys-C, and the result-
ing peptide fragments were resolved by HPLC (Fig. 1) and
analyzed by MALDI/TOF/MS. A separate digestion was carried
out with CNBr. As shown in Table I, about 75% of the entire
sequence of the glycosylated protein could be mapped from the
two sets of peptides, and of the seven potential N-linked glyco-
sylation sites, four (Asn155, Asn337, Asn586, and Asn620) were
found unglycosylated. The CNBr fragment Leu593-Arg627 is
thought to be the COOH terminus of the soluble form of ACE
FIG. 1. HPLC chromatogram of a Lys-C digest of wild-type
tACE. The peptide mixture was injected onto a C18 Delta-Pak column
(Waters) and developed with a linear gradient of 8.5–51% acetonitrile in
0.1% trifluoroacetic acid over 90 min. Fractions designated by an aster-
isk provided no assignable MALDI/TOF/MS signals (did not match the
mass of any peptide) and were thus digested further with glycosidases
and analyzed as described under “Experimental Procedures.”


























from CHO cells, as discussed in more detail elsewhere (8).
All of the peptides that make up the remaining 25% of the
protein sequence not observed prior to deglycosylation contain
potential N- and/or O-linked glycosylation sites. To determine
unambiguously the glycosylation states of Asn residues in all
seven sequons, the oligosaccharides were removed by treat-
ment with a series of glycosidases. HPLC fractions from the
CNBr and Lys-C digests that did not contain identifiable pep-
tides (Fig. 1) were treated with a mixture of peptide N-glyco-
sidase F, neuraminidase, and O-glycosidase. Subsequent mo-
lecular mass determination by MALDI/TOF/MS identified four
peptides, each of which contains at least one of the potentially
glycosylated Asn residues.
The mass spectrum of the first CNBr-peptide identified after
the removal of oligosaccharides is shown in Fig. 2. The ob-
served peak at m/z 6506.2 agrees well with 6509.5 calculated
for peptide Gln87-Hse (Met142), assuming both potential sites,
Asn90 and Asn109, were originally glycosylated and converted
to Asp by peptideN-glycosidase F. To determine whether one or
both residues are indeed glycosylated in the native ACE, the
peptide was treated with endoproteinase Asp-N, which would
cleave at Asp residues (including those newly generated) but
not at Asn residues. After HPLC separation of the digest and
MALDI/TOF/MS analysis of the fractions, both expected pep-
tides, Asp90-Phe102 and Asp109-Gln120 were observed (Fig. 3) as
molecular ions at m/z 1566.3 (calculated 1565.8) and 1444.5
(calculated 1443.8), respectively. These results are consistent
with glycosylation at both Asn90 and Asn109.
To confirm these findings, the original, glycosylated CNBr-
peptide Gln87-Hse (Met142) was treated with Asp-N, the digests
were separated by HPLC, and the resulting fractions were
analyzed by MALDI/TOF/MS. The spectra of two fractions
(Figs. 4A and 5A, respectively) exhibited typical glyco-patterns
(clusters of peaks separated by 162, 203, and 291 Da, corre-
sponding to the addition of hexose, N-acetylhexosamine, and
sialic acid residues, respectively) indicating the presence of
heterogeneous N-linked glycans. After treatment with glycosi-
dases, these multiplets converged to a single dominant peak
(Figs. 4B and Fig. 5B). They were identified as peptide Asp103-
Gln120 (Fig. 4B, expected m/z 2141.5) and Gln87-Phe102 (Fig.
5B, expected m/z 1878.2). Thus both Asn90 and Asn109 are
glycosylated in the wild-type tACE.
As shown in Fig. 4A, the different molecular ions observed in
the glycosylated peptide Asp103-Gln120 demonstrate the heter-
ogeneous nature of the sugars attached to Asn109. The mass
difference between the molecular ion at m/z 3910.1 and m/z
2141.5 (calculated for the deglycosylated peptide) is 1768.6,
consistent with the calculated value of 1769.6 for the increment
in molecular mass due to the addition of Hex5HexNAc4Deoxy-
Hex1 to Asn
109. These data indicate that the N-linked glycans
in tACE are mostly of the biantennary, fucosylated complex
FIG. 2.MALDI/TOF/MS of a peptide N-glycosidase F deglycosylated CNBr fragment from tACE. The peaks at m/z 6506.2, 3254.5, and
2170.2 correspond to the singly, doubly, and triply protonated peptide Gln87-Hse (Met142), which contains two potential glycosylation sites, Asn90
and Asn109. Xn refers to spacing by n amino acids.
TABLE I
Observed [M1H]1 ions of unglycosylated peptides in
human testis ACE
Peptide Fraction Calculated m/z Observed m/z
Lys-C
80–84a 1 614.8 614.5
118–137 10 2,345.6 2,344.5
175–188 22 1,868.1 1,868.7
189–307 43 13,716.6 13,713.8
308–317 8 1,307.6 1,307.1
318–338b 28 2,423.7 2,424.8
339–363 12 2,842.2 2,841.8
364–368 5 678.8 678.7
369–395 18 3,236.7 3,235.7
396–425 21 3,075.5 3,074.8
426–449 34 2,695.0 2,693.3
455–478 30 2,946.4 2,946.4
479–491 15 1,766.9 1,766.6
492–511 9 2,147.4 2,146.7
512–556 36 5,224.0 5,223.4
557–567 2 1,176.4 1,176.3
568–613 37 5,293.1 5,293.2












a Numbered according to the sequence of the wild-type protein (13).
b Bold characters indicate peptides that contain potential N-glycosy-
lation sites.
c Calculated for COOH-terminal homoserine lactone.


























type (Fig. 6). The addition of either one or two sialic acids at the
two termini would produce molecular ions at m/z 4201.4 (ob-
served at m/z 4201.4) and 4492.7 (observed at m/z 4492.6). The
presence of shorter glycans was also observed in the spectrum
shown in Fig. 4A. The likely compositions of the various car-
bohydrate moieties attached to Asn109 are listed in the inset.
The glycan structures on Asn90 as deduced from the mass
spectrum are listed in Fig. 5A. The mass difference between the
molecular ion at m/z 3646.9 and the deglycosylated calculated
peptide mass at 1878.2 is 1768.7, again consistent with the
calculated mass of 1769.6 for the above oligosaccharide incre-
ment. Masses corresponding to the addition of one and two
sialic acids, respectively, as well as shorter glycans are appar-
ent in the spectrum (Fig. 5A).
Three residues, Asn155, Asn337, and Asn586, are present in
both glycosylated and unglycosylated forms. As mentioned ear-
lier, peptides with these three sequons were observed in their
unglycosylated forms (see Table I). Based on the molecular
mass of the observed major oligosaccharide structure (1769.6),
it was possible to identify them in their glycosylated forms as
well (Table II). For Asn155, the same molecular ions were ob-
served before and after incubation with the glycosidases, which
may be due to the presence of a disulfide bond between Cys152
and Cys158 (see discussion below) which may prevent enzy-
matic deglycosylation. For Asn586, a molecular ion at m/z
5309.1 was observed after glycosidase treatment, which is 16
Da higher than that expected for deglycosylated peptide
Leu568-Lys613 (calculatedm/z 5294.1). This is most likely due to
oxidation of one or more of the three Met residues present in
that peptide (peaks 32 and 48 Da higher and of decreasing
signal intensity are also present).
As listed in Table II, molecular ions were also observed
which suggest the glycosylation of Asn72. This is based on the
assumption that the same type of oligosaccharide structure is
attached to this site but lacks the fucose moiety. However, the
amount of peptide recovered after treatment with deglycosi-
dases was insufficient for positive identification.
Identification of N-Linked Glycosylation Sites in Purified
Human Kidney ACE—Automated peptide sequencing was ap-
plied to tryptic fragments of somatic ACE isolated from human
FIG. 3. MALDI/TOF/MS of peptides obtained by Asp-N digestion of peptide N-glycosidase F deglycosylated peptide Gln87-Hse
(Met142). Panel A corresponds to the protonated peptide Asp90-Phe102 and panel B to the protonated peptide Asp109-Gln120.


























kidney. A total of 28 tryptic peptides was identified (Table III),
among which six contained glycosylated Asn residues (residues
9, 25, 82, 117, 480, and 913), and one contained an unglycosy-
lated Asn (residue 1196). There are 17 N-glycosylation sequons
in human somatic ACE, and the states of glycosylation of the
remaining 10 potential sites were not determined in this study.
Effects of NB-DNJ and Treatment of ACED36NJ with Endo
H—The deletion mutant tACED36NJ lacks the first 36 NH2-
terminal residues of the mature protein (7); it is also truncated
after Ser625 to encode a soluble protein that lacks part of the
juxtamembrane stalk and the transmembrane and cytoplasmic
domains (these modifications were introduced to facilitate later
crystallization attempts). The glucosidase I inhibitor NB-DNJ
prevents maturation of N-linked oligosaccharides of recombi-
nant protein expressed in CHO cells (14). These sugars remain
as oligomannose forms that are cleaved with endoglycosidase H
FIG. 4. Panel A, MALDI/TOF/MS of an HPLC fraction from the Asp-N digest of CNBr-glycopeptide Gln87-Hse (Met142). The multiple peaks from
m/z 3000 to 4800 show the glycoform distribution. Panel B, MALDI/TOF/MS of the above fraction after treatment with a mixture of glycosidases.
The peak at m/z 2142.1 corresponds to the protonated peptide Asp103-Gln120.


























under nondenaturing conditions to leave single N-acetylglu-
cosamine residues (12).
After expression in the presence of NB-DNJ, tACED36NJ
migrated as a sharp band on SDS-polyacrylamide gel electro-
phoresis (Fig. 7) consistent with increased homogeneity of its
N-linked oligosaccharides. Digestion of this protein with en-
doglycosidase H produced an electrophoretically homogeneous
product at 68 kDa, in agreement with mass spectrometric anal-
ysis that gave a [M1H]1 ion at m/z 68,924 (expected m/z
69,008, with five GlcNAc/mol of protein). The glycosylated pro-
tein (tACED36NJ) from cells not treated with NB-DNJ was
found to be present as a multiplet at m/z 74,136. The different
FIG. 5. Panel A, MALDI/TOF/MS of a HPLC fraction from an Asp-N digest of CNBr-glycopeptide Gln87-Hse (Met142). The multiple peaks from
m/z 3000 to 4500 show the glycoform distribution. Panel B, MALDI/TOF/MS of the above fraction after treatment with a mixture of glycosidases.
The peak at m/z 1877.8 is due to protonated peptide Gln87-Phe102. The peak at 1860.1 is the same peptide in which the NH2-terminal Gln has
cyclized to pyroglutamic acid. The 17-Da doublets can also be observed in panel A.


























glycoforms of the mutant protein as well as those of the wild-
type tACE migrated as broad diffuse bands on SDS-polyacryl-
amide gel electrophoresis with molecular masses of approxi-
mately 75 and 84 kDa, respectively (Fig. 7).
Catalytic Properties—tACED36NJ retained its enzyme activ-
ity after deglycosylation with endoglycosidase H. The specific
activity of the glycosylated protein, in terms of the hydrolysis of
furanacryloyl-Phe-Gly-Gly, was somewhat higher than that of
the deglycosylated form as reflected in the values for kcat
(22,876 min21 for the glycosylated form and 20,500 for the
deglycosylated form). However, its Km was unchanged: 2.00
and 2.03 3 1024 M for the glycosylated and deglycosylated
forms, respectively. The kcat and Km values of the deglycosy-
lated protein were in agreement with those reported for the
wild-type tACE (11).
DISCUSSION
Glycosylation is an essential feature of the biosynthesis of
ACE. Rabbit tACE, transiently expressed in human HeLa cells
in the presence of tunicamycin, a chemical inhibitor ofN-linked
glycosylation, appeared only in the cytosol and was degraded
rapidly (4). Studies of partial glycosylation of tACE by muta-
tion of potential N-linked glycosylation sites indicated that the
oligosaccharide chains at each site make different contribu-
tions to in vivo stability and localization (6). Such selective
effects are not unprecedented. For example, in the case of the
human vasoactive intestinal peptide I receptor it was reported
that Asn58 or Asn69 is critical for its correct delivery to the
plasma membrane (15), and glycans at Asn25 in human inter-
feron-g were found to confer protease resistance (16). We have
identified three fully glycosylated and three partially glycosy-
lated Asn residues among the seven N-glycosylation sequons in
human tACE when the enzyme is expressed in CHO cells. Our
results are similar to those obtained with rabbit tACE (6) in
that all five conserved potential glycosylation sites are glyco-
sylated. Three of these five are located near the NH2 terminus
of the enzyme, and either of the first two was found to be
sufficient for the release of rabbit tACE (6). Our observation is
consistent with the suggestion that glycosylation at these sites
is probably involved in recognition and intracellular transport
during later stages of enzyme biosynthesis.
The potential glycosylation site Asn155 was found to be pres-
ent in both glycosylated and unglycosylated forms. It is inter-
esting to note that Asn155 is located between cysteines 152 and
158, which form a disulfide bond (17), and it is “homologous” to
Asn131 in somatic ACE. We have suggested that specific disul-
fide formations in ACE could be critical in its folding process
(17). This would be consistent with the report that ACE ex-
pressed in E. coli did not have a conformation that generated
enzymatic activity (6). It appears that glycosylation processes
in either the ER or Golgi may be affected by disulfide forma-
tion. Specific constraints imposed by the disulfide linkage be-
tween Cys152 and Cys158 in human tACE may prevent or re-
duce oligosaccharide attachment at Asn155 much as it seems to
prevent enzymatic deglycosylation (see above). In fact, Asn155
is replaced by an Asp in rabbit tACE, whereas the positions of
the two cysteines are conserved. It was demonstrated that
conditions that prevent disulfide bond formation in tissue-type
plasminogen activator allow complete glycosylation of a sequon
that is otherwise variably glycosylated (18). Thus it may well
be that mutations of cysteines that form the three disulfide
bonds in tACE would not only affect folding but also affect
glycosylation and consequently its transport and release.
A summary of the N-glycosylation state of the seven sequons
is presented in (Fig. 6). It is interesting that the fully glycosy-
lated sequons all end with threonine, whereas those that are
only partially glycosylated end with serine. This agrees with
the recent report that when serine is in the third position,
glycosylation is less complete than in the case of threonine (19).
For Asn155 the effect of the disulfide bond discussed above may
be an additional factor in reducing the level of glycosylation.
Indeed, the particular order in which folding, disulfide forma-
tion, and other post-translational modifications occur within
the ER will likely determine the accessibility of sequons to core
glycosylation.
FIG. 6. Proposed structure of the most extended N-linked
oligosaccharide.
TABLE II
Observed [M1H]1 ions of glycosylated peptides in human testis ACE
Sequon Peptide Peptide 1 carbohydrate
Before deglycosylation After deglycosylation
Calc. m/z Obsd. m/z Calc. m/z Obsd. m/z
Asn72 47–79a 4004.2 1 1769.6-Fuc 5627.7 5626.3
1NeuAC 5919.0 2920.4
1NeuAC 6210.3 6211.6
Asn90 87–102b 1877.2 1 1769.6 3646.7 3646.6 1878.2 1877.8
1NeuAC 3938.0 3937.5
1NeuAC 4229.3 4228.9
Asn109 103–120b 2140.5 1 1769.6 3910.2 3910.1 2141.5 2142.1
2(GlcNAc-Gal) 3544.8 3545.0
2Gal 3748.0 3748.1
2Gal 1 NeuAC 4039.3 4039.2
1NeuAC 4201.4 4201.6
Asn155 138–188a 5902.7 1 1769.6 7673.4 7669.1
1NeuAC 7964.7 7960.3
1NeuAC 8256.0 8252.2
Asn337 318–338a 2423.7 1 1769.6 4192.3 4216.0c 2424.7 2425.1
1NeuAC 4484.6 4496.8c
1NeuAC 4775.9 4781.6c
Asn586 568–613a 5293.1 1 1769.6 7062.7 7062.2 5294.1 5309.1d
1NeuAC 7354.0 7353.2
1NeuAC 7645.3 7644.8
a Peptides were isolated from Lys-C digestion.
b Peptides were isolated from CNBr and Asp-N digestions.
c Large error due to low signal-to-noise ratio.
d Mass increase due to oxidation of Met.


























The only unglycosylated site in tACE was identified at
Asn620. It has been shown that ACE is released from the
plasma membrane of the CHO cells into the medium by a
cleavage between Arg627 and Ser628 (8, 20). The exact nature of
the protease(s) involved in the cleavage reaction is not clear,
but it is possible that if the nearby Asn620 was glycosylated,
this proteolytic modification might be sterically hindered. In-
deed, this potential glycosylation site is absent in rabbit and
mouse. From our initial analyses of human somatic ACE,
Asn1196, which corresponds to Asn620 of tACE, was also not
glycosylated. Sequons at the COOH-terminal ends of proteins
are often found to be unglycosylated. The present observations
would seem to be another example of this general but not well
understood phenomenon.
Our sequencing analysis of somatic ACE, although not yet
complete, provides interesting information on N-linked glyco-
sylation sites. Human seminal plasma ACE has been reported
to consist of 14% carbohydrate by weight and to have approx-
imately seven N-linked glycosylation sites (3). Whereas human
kidney ACEmay have slightly more carbohydrate, it is possible
that we have identified most if not all of its glycosylated Asn
sites and that the general pattern observed is, perhaps not
surprisingly, similar to that seen in tACE (Fig. 7). Both
isozymes are heavily glycosylated at their NH2 termini, with
the Asn in sequon Asn-Lys-Ser glycosylated in both isozymes
(Asn337 in tACE and Asn913 in somatic ACE). Further to the
discussion above, it is likely that carbohydrates attached at the
NH2 termini of the ACE proteins are used as general signals in
trafficking to the plasma membrane. This concept is consistent
with the observation by Sadhukhan and Sen and (6) that only
one sequon at the NH2 terminus of the rabbit tACE was nec-
essary and sufficient for tACE release, but the exact site of that
sequon was not critical. On the other hand, it is tempting to
speculate that the oligosaccharide chain on Asn-Lys-Ser in
both isozymes may play a more specific functional role in ACE,
as the nearby zinc binding site and the disulfide-linked cys-
teines are located in a region where sequence homology is
significantly higher. It should be noted, however, that the se-
quence of residues 36–701 of tACE is identical to that of resi-
dues 613–1277 (the COOH-terminal domain) of somatic ACE.
Yet although six of the seven sequons in tACE are glycosylated,
the limited evidence (Table III) suggests that only one is gly-
cosylated in the corresponding segment of somatic ACE. More-
over, while the N- and C- domains of somatic ACE are homol-
ogous only one of the 10 sequons in the former has a
counterpart in the latter. The five that are glycosylated have no
equivalent sequons. Thus, the similarity of glycosylation pat-
terns seen in somatic and tACE (Fig. 8) seems to be determined
by the order in which sequons enter the ER rather than by
overall sequence.
It remains unclear whether and which glycosylation sites
influence the transport, release, and stability of ACE. Naim (5)
reported that selective inhibition of glucosidases I and II in the
ER and mannosidase I in the Golgi causes a significant delay in
intestinal ACE secretion. In addition, rabbit tACE appeared to
be trapped intracellularly and undergo rapid degradation in
tunicamycin-treated human HeLa cells. These observations
would be consistent with the concept that a specific interaction
between oligosaccharides and the folding machinery in the ER
is required for proper protein processing in eukaryotic cells. It
was demonstrated that mutations in glycosylation sites in the
human immunoglobulin E receptor a-subunit caused misfold-
ing and retention of the protein in the ER (21). Glycosylation
may also affect protein secretion in a more direct way (22). It
has been documented that N-glycans in properly folded lysoso-
mal enzymes are recognized by a specific mechanism in the
Golgi which generates a mannose 6-phosphate marker critical
FIG. 7. SDS-polyacrylamide gel electrophoresis of wild-type
andmutant tACE on 4–20% gradient gel stained with Coomassie
Brilliant Blue. Lane 1, wild-type tACE; lane 2, tACED36NJ; lane 3,
endoglycosidase H-treated tACED36NJ; lane 4, molecular mass
markers.
TABLE III
Tryptic peptides from human kidney ACE identified by
Edman sequencing





























a Identified as glycosylated by the absence of Asn peak. Sample was
not treated with peptide N-glycosidase F.
b Identified as glycosylated by the presence of Asp peak. Sample was
treated with peptide N-glycosidase F.
c Identified as not glycosylated by the presence of Asn peak. Sample
was treated with peptide N-glycosidase F.
FIG. 8. Schematic representations of testis and somatic ACE
showing the relative positions of theN-linked sites identified as
being glycosylated only (closed box), glycosylated and nongly-
cosylated (dotted box), and nonglycosylated only (open box).


























to their delivery via endocytic pathways (23). Scheiffele et al.
(24) demonstrated that nonglycosylated growth hormone is
secreted both apically and basolaterally but only apically when
glycosylated.
Structural studies of ACE have long been hampered by an
inability to crystallize the enzyme. It is thought that the re-
moval of the carbohydrates on ACE may help alleviate this
problem. As tACE expressed in E. coli is catalytically inactive
(6), enzymatic removal of oligosaccharides appears to be a
promising alternative strategy. Complete enzymatic deglycosy-
lation can only occur when ACE is denatured. To obtain struc-
turally meaningful information on the active site of ACE, it is
essential that the deglycosylated ACE retains its native con-
formation and is enzymatically active. Our results show that
the NB-DNJ-treated ACE mutant digested with endoglycosi-
dase H is deglycosylated yet fully active. (It actually retains a
single N-acetylglucosamine residue at each glycosylation site
but should be devoid of oligosaccharide-based heterogeneity.)
This form of ACE is thus considered a good candidate for
crystallographic studies. Our results further support the notion
that in vivo, glycosylation confers higher stability and plays a
role in the transport and release of ACE.
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